Department of Chemistry and Biochemistry, Ohio University, Athens, OH 45701-2979, USA.
Br J Pharmacol. 2009 Apr;156(8):1256-66. doi: 10.1111/j.1476-5381.2009.00125.x. Epub 2009 Feb 18.
The pleiotropic effects of HMG-CoA inhibitors (statins), which include anti-inflammation, antioxidation and immunomodulation, are not yet fully understood. The present study was designed to elucidate the role of nitric oxide (NO), peroxynitrite (ONOO(-)) and haem oxygenase-1 (HO-1) in the anti-atherogenic effect of statins.
Normal and atherosclerotic New Zealand rabbits were treated with atorvastatin or simvastatin in the presence or absence of inhibitors and promoters of endothelial nitric oxide synthase (eNOS) and HO-1. NO and ONOO(-) released from isolated aortae by calcium ionophore were measured with nanosensors placed 6 +/- 2 nm from aortic endothelium. Expression of eNOS and HO-1 protein, HO activity, plasma malondialdehyde (MDA) and vessel wall thickness were also measured.
Hypercholesterolaemia decreased eNOS expression by 31 +/- 3%, decreased NO (230 +/- 16 vs. 433 +/- 17 nmol x L(-1) control) and increased cytotoxic ONOO(-) (299 +/- 15 vs. 187 +/- 11 nmol x L(-1) control). The concentration ratio of [NO]/[ONOO(-)] decreased from 2.3 +/- 0.1 (normal) to 0.7 +/- 0.1 indicating an increase of nitroxidative stress in atherosclerotic endothelium. Expression of HO-1 protein increased by 20 +/- 8% in atherosclerosis and further increased (about 30%) after treatment with statins. Statins partially restored the [NO]/[ONOO(-)] balance (1.5 +/- 0.1 for atorvastatin and 1.4 +/- 0.1 simvastatin), decreased MDA and wall thickening. Promoters of eNOS and HO-1 (L-arginine and haemin) ameliorated the [NO]/[ONOO(-)] ratio while their inhibitors (L-NAME or tin-protoporphyrin) showed no improvement in these ratio.
Atherosclerosis induced an endothelial [NO]/[ONOO(-)] balance indicative of endothelial dysfunction. Statins showed anti-atherosclerotic effects mediated by HO-1/eNOS, restoring the [NO]/[ONOO(-)] imbalance and reducing lipid peroxidation.
HMG-CoA 抑制剂(他汀类药物)具有多种效应,包括抗炎、抗氧化和免疫调节,但目前仍不完全清楚。本研究旨在阐明一氧化氮(NO)、过氧亚硝酸盐(ONOO(-))和血红素加氧酶-1(HO-1)在他汀类药物抗动脉粥样硬化中的作用。
用阿托伐他汀或辛伐他汀在新西兰正常和动脉粥样硬化兔中进行治疗,同时存在或不存在内皮型一氧化氮合酶(eNOS)和 HO-1 的抑制剂和促进剂。用纳米传感器测量钙离子载体从分离的主动脉中释放的 NO 和 ONOO(-),纳米传感器距离主动脉内皮 6 +/- 2nm。还测量了 eNOS 和 HO-1 蛋白的表达、HO 活性、血浆丙二醛(MDA)和血管壁厚度。
高胆固醇血症使 eNOS 表达减少 31 +/- 3%,使 NO(230 +/- 16 比对照 433 +/- 17 nmol x L(-1))减少,使细胞毒性 ONOO(-)增加(299 +/- 15 比对照 187 +/- 11 nmol x L(-1))。[NO]/[ONOO(-)]浓度比从正常的 2.3 +/- 0.1 下降到 0.7 +/- 0.1,表明动脉粥样硬化内皮的硝自由基应激增加。HO-1 蛋白在动脉粥样硬化中增加 20 +/- 8%,在用他汀类药物治疗后进一步增加(约 30%)。他汀类药物部分恢复了 [NO]/[ONOO(-)]平衡(阿托伐他汀为 1.5 +/- 0.1,辛伐他汀为 1.4 +/- 0.1),降低了 MDA 和壁增厚。eNOS 和 HO-1 的促进剂(L-精氨酸和血红素)改善了 [NO]/[ONOO(-)] 比值,而它们的抑制剂(L-NAME 或锡原卟啉)则不能改善这一比值。
动脉粥样硬化引起内皮 [NO]/[ONOO(-)] 平衡失调,提示内皮功能障碍。他汀类药物通过 HO-1/eNOS 显示出抗动脉粥样硬化作用,恢复了 [NO]/[ONOO(-)] 失衡并减少脂质过氧化。